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Abstract Objective To investigate differences in oxytocin (OXT) biodistribution between
nonobese and obese parturients during labor.
Study Design Patients with body mass index (BMI) of either  18  24.9 kg/m2
(“nonobese”) or  30 kg/m2 (“obese”) undergoing elective induction of labor were
included (N ¼ 25 each). Blood samples were collected at baseline (T0), and 20 minutes
after maximal OXT augmentation or adequate uterine contractions (T1) for OXT and
oxytocinase assays. A mixed-model repeated-measures analysis of variance was used to
test for group versus time interaction and analysis of covariance to detect a difference
in OXT level at T1. Data presented as mean  standard deviation or median (inter-
quartile range), with p < 0.05 considered significant.
Results Themean BMIs (kg/m2) were 22.1  1.6 and 35.9  5.1 in the nonobese and
obese groups, respectively. No differences were observed in either the duration of OXT
infusion, total dose of OXT, or plasma OXT (pg/mL) either at T0 or T1. However, plasma
oxytocinase (ng/mL) was significantly lower at T0 (1.41 [0.67, 3.51] vs. 0.40 [0.29,
1.12]; p ¼ 0.03) in the obese group.
Conclusion We provide preliminary evidence that the disposition of OXT may not be
different between obese and nonobese women during labor.
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In the United States, more than one-third of pregnant women
are obese (prepregnancy body mass index [BMI]  30 kg/
m2),1,2 and have an approximate 35% risk of cesarean delivery
(CD) especially during the first stage of labor.3–5 Though
increased risk for CD in this population is likely multifactor-
ial,6,7 labor dystocia appears to play a predominant role. The
diagnosis of labor dystocia, however, is predicated on the
assumption that labor curves are similar for both groups,
and that the pharmacokinetics of oxytocin (OXT) used for
labor augmentation is comparable between obese and non-
obese parturients. It is now known that labor curves are
different in obese and nonobese parturients8,9; however, no
study has directly examined differences in pharmacokinetics
of OXT between these two groups. Especially, differences in
BMI account for one-fifth of variability in OXT requirements
during labor.10This isa criticalknowledgegapconsidering that
there are significant differences in pharmacokinetic para-
meters between obese and nonobese patients in the nonob-
stetric setting,11,12 along with preclinical data suggesting that
obesity is associated with lower OXT and higher oxytocinase
activity.13 Therefore, in this preliminary study, we hypothe-
sized that obese women will have lower plasma OXT and a
higher plasma oxytocinase level at baseline compared with
nonobese women. Furthermore, because of the increased
volume of distribution in obesity,11 we speculated that the
magnitude of rise in plasma OXT will be lower in obese
compared with nonobese women during labor augmentation
with OXT. To investigate this hypothesis, we designed a pro-
spective, observational cohort study to compare the plasma
levels of OXT and oxytocinase in obese and nonobese women
at both induction and during augmentation of labor.
Methods
This prospective, observational cohort study was conducted
after appropriate Institutional Research Board approval (#
2015P002040) at the labor and delivery unit of the Brigham
andWomen’s Hospital, a tertiary-care center with an annual
clinical volume of 7,000 births. All methods reported here
were performed in accordance with institutional guidelines
and regulations, and complies with all recommendations
suggested by the STROBE statement.14 Patients at term
gestation ( 37 weeks) were eligible for enrollment if they
were older than the age of 18 years, undergoing induction of
labor with OXT, and had a prepregnancy BMI of
either  18  24.9 kg/m2 (“nonobese”) or  30 kg/m2
(“obese”). Patients were excluded if they presented in labor,
were overweight (prepregnancy BMI of 25–29.9 kg/m2), or
had a relative contraindication tovenipuncture (suspected or
known coagulopathy, or hematologic disorder). Patient
recruitment occurred between November 2015 and
April 2017. Eligible patients were approached by a research
investigator at the time of admission to labor and delivery
unit and provided with an information sheet that explained
the purpose of the study. Patients who expressed interest
were recruited after a thorough history and clinical exam-
ination and a formalwritten informed consent. Each enrolled
participant was assigned a sequential subject identification
number, and all pertinent demographic information were
collected.
A baseline basal blood sample (10 mL) was collected from
each participant at the time of placement of an intravenous
(IV) catheter prior to initiation of OXT infusion (T0). A second
blood sample (10 mL) was collected from the opposite arm
when no further increase in OXTwas likely (either 3–5 uterine
contractions in a 10-minute period or at a maximal OXT
augmentationrateof20mIU/min) (T1). This samplewasdrawn
from the arm opposite to the arm with the IV catheter. Blood
sampleswere collected into BDVacutainer containing 10.8 mg
of K2 EDTA, immediately placed on ice, centrifuged at
1,600  g for 15 minutes at 4°C, and the resultant plasma
stored at 80°C before assays. For the OXT assay, plasma was
thawed, C-18 extracted, and assayed in duplicate using a
commercially available OXT ELISA kit (EIA kit # EK-051-01,
Phoenix Pharmaceuticals, Inc.). Oxytocinase was assayed in
unextracted plasma using the human LNPEP (leucyl-cystinyl
aminopeptidase) sandwich ELISA kit (# LS-F11924, Lifespan
Biosciences, Inc.) according to manufacturer’s instructions.
Data on OXT use, total cumulative OXT dose until T1, and
duration of OXT administration (from T0 toT1) were collected.
The study was terminated after collection of the T1 sample.
Statistical Analysis
Our primary outcome was to determine if there was a
baseline difference in plasma OXT between the obese and
nonobese groups at induction of labor. Our secondary out-
comes were differences in oxytocinase levels and the mag-
nitude of change in plasma OXT from T0 to T1 in both groups
during labor augmentation. Given a mean baseline OXT level
of 45 pg/mL and standard deviation of 20 pg/mL in nonobese
parturients,15 we estimated that 19 patients would be
required per group to show a 40% decrease in plasma OXT
in the obese group for an α of 0.05 and 80% power. Because of
the unpredictability of labor and challenges in the expedi-
tious processing of samples after hours, we decided to enroll
25 patients per group to account for the possible attrition.
Numeric variables were compared with either independent
sample t-tests or Wilcoxon’s rank-sum test for data with
significant outliers. Categorical variables were compared
with Pearson’s chi-square or Fisher’s exact tests as appro-
priate. To test for interaction between BMI category and the
magnitude of change from T0 toT1, a mixed-model repeated-
measures ANOVA was used. If group versus time interaction
was not significant, the analysis was re-run without the
interaction term. In addition, an analysis of covariance was
performed to determine if therewas a difference in OXT level
at T1 after adjusting for the difference in oxytocinase level at
T0 and cumulative OXT dose. Correlations between cumula-
tive OXT dose and OXT and oxytocinase were determined
using Spearman’s correlation. Data are presented either as
median (interquartile range), mean  standard deviation, or
% as appropriate. All tests were two tailed and a p-value
of < 0.05 was accorded statistical significance. The data
analysis for this article was generated using SAS software,
version 9.3 of the SAS System for Windows. Copyright 2010
SAS Institute Inc (Cary, NC).
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Results
A total of 56 eligible patients were approached for the study.
Five declined participation (two nonobese and three obese
patients), and one nonobese patient was rescheduled for
induction at a later date. Overall, we recruited 25 nonobese
and obese subjects each for the study. T0 samples were
obtained in 23/25 patients in both groups. T1 samples
were obtained in 19/25 subjects in the nonobese and 13/
25 in the obese groups. Paired samples (both T0 and T1
samples from the same patient) were available for 18/25
nonobese and 12/25 obese subjects. All samples were
assayed for plasma OXT. Because of inadequate sample
volume, oxytocinase assay was not performed in one patient
in the nonobese and two patients in the obese groups at T0,
and two patients in the nonobese and one patient in the
obese groups at T1. The flowchart detailing patient recruit-
ment is presented in ►Fig. 1.
Both groups were well matched at baseline except for a
higher proportion of cervical ripening in obese (48%) com-
pared with nonobese (8%) patients (p ¼ 0.002, ►Table 1).
Details of OXT and oxytocinase levels at T0 and T1, total
cumulative dose of OXT administered until T1, and duration
of OXT administration are presented in ►Table 2. There were
no differences either in the plasma OXT level at T0 (351 [56,
790] vs. 135 [14, 534] pg/mL; p ¼ 0.39) and T1 (463 [15, 791]
vs. 320 [14, 768] pg/mL; p ¼ 0.95) (►Fig. 2). However, plasma
oxytocinase was significantly lower at T0 in the obese group
(1.41 [0.67, 3.51] vs. 0.40 [0.29, 1.12] ng/mL; p ¼ 0.03) but not
at T1 (1.35 [0.67, 3.53] vs. 0.32 [0.18, 4.03] ng/mL, nonobese
versus obese, respectively; p ¼ 0.44) (►Fig. 3). Similarly, there
was no difference in the total cumulative dose of OXTreceived
during the study (3,396  1,602 vs. 3,793  2,819 mIU;
p ¼ 0.65) nor was there a difference in the total duration of
OXT administration (397  159 vs. 537  629 minutes;
p ¼ 0.45) between the nonobese and obese groups.
Fig. 1 A detailed flowchart indicating patient recruitment and sample collection during the course of the study.
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In paired samples from12/18 (67%) in the nonobese group
and 7/12 (58%) in the obese group, plasma OXT level
decreased from baseline after OXT augmentation (►Fig. 4).
Neither the T1  T0 difference for OXT (6.50 [96.00, 4.00]
vs. 1.50 [41.00, 6.50] pg/mL; p ¼ 0.70) nor oxytocinase
(0.19 [0.00, 0.46] vs. 0.05 [0.03, 0.14] ng/mL; p ¼ 0.22)
were statistically significant between the nonobese and
obese groups, respectively (►Table 2). There was no
Table 1 Demographic and labor induction data in nonobese and obese parturients
Nonobese Obese p-Value
n Mean  SD or % n Mean  SD or %
Age (y) 25 31.32  4.47 25 33.04  5.31 0.40
BMI (kg/m2) 25 22.13  1.59 25 35.89  5.09 <0.0001
Gestational age (wk) 25 39.24  1.05 25 39.00  1.26 0.48
Gestational weight gain (kg) 25 15.2  5.5 19 12.8  4.4 0.13
Multiparity 12 48 17 68 0.44
Cervical ripening 2 8 12 48 0.002
Maximal oxytocin augmentation 4 16 7 28 0.50
Artificial rupture of membranes 21 84 20 80 0.71
Vaginal delivery 24 96 21 84 0.35
Cesarean delivery 1 4 4 16
Abbreviations: BMI, body mass index; SD, standard deviation.
Table 2 Oxytocin and oxytocinase data in nonobese and obese parturients
Nonobese Obese p-Value
n Median (IQR) or
Mean  SD
n Median (IQR) or
Mean  SD
Oxytocin T0 (pg/mL) 23 351 (56, 790) 23 135 (14, 534) 0.39
Oxytocin T1 (pg/mL) 19 463 (15, 791) 13 320 (14, 768) 0.95
Oxytocinase T0 (ng/mL) 22 1.41 (0.67, 3.51) 21 0.40 (0.29, 1.12) 0.03
Oxytocinase T1 (ng/mL) 17 1.35 (0.67, 3.53) 12 0.32 (0.18, 4.03) 0.44
Cumulative oxytocin dose (mIU) 19 3,396  1,602 13 3,793  2,820 0.65
Duration of oxytocin administration (min) 19 397.5  159.2 13 537.3  629.3 0.45
T1  T0 oxytocin (pg/mL) 18 6.50 (96.00, 4.00) 12 1.50 (41.00, 6.50) 0.70
T1  T0 oxytocinase (ng/mL) 17 0.19 (0.00, 0.46) 9 0.05 (0.03, 0.14) 0.22
Abbreviations: IQR, interquartile range; SD, standard deviation.
Fig. 2 Scatter plot of plasma oxytocin level (pg/mL) in nonobese (in circles) and obese parturients (in squares) during labor induction and
augmentation at time T0 (open shapes) and T1 (closed shapes). There were no significant differences in plasma oxytocin level either at T0
(p ¼ 0.39) or at T1 (p ¼ 0.95). Data represented as median and interquartile range.
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significant groupversus time interaction in change fromT0 to
T1 for both OXT (p ¼ 0.51) and oxytocinase (p ¼ 0.09);
therefore, the analysis was re-run without the interaction
term. There was neither a significant group (p ¼ 0.91 and
0.76) nor a time effect (p ¼ 0.56 and 0.22) for either OXT or
oxytocinase, respectively (►Table 3). As cumulative OXT had
significant correlations with oxytocinase both at T0 and T1,
we analyzed only patients with cumulative OXT data with
(►Table 4) and without (►Table 5) cumulative OXT dose as a
covariate, but it did not change the overall conclusions.
Finally, there was no significant difference in the OXT level
at T1 between the two groups even after adjusting for the
difference in oxytocinase at baseline (T0) (p ¼ 0.34)
(►Table 6).
Discussion
In this preliminary study, we show that plasma OXT levels
were comparable between nonobese and obese women
undergoing induction of labor at term gestation, either at
baseline or after OXT augmentation. Furthermore, the mag-
nitude of change in plasma OXT level from baseline was no
different in either the nonobese or obese women. Interest-
ingly, and contrary to prevailing notion, plasma OXT was
lower after OXT augmentation compared with baseline
values in a majority of patients with paired samples. Collec-
tively, our data suggest that differences in labor outcomes
between obese and nonobese parturients are unlikely due to
differences in OXT disposition and lay the foundation for a
comprehensive pharmacokinetic study.
A prominent feature of our results was the high inter-
individual variability of plasma OXT in parturients even at
baseline. This variability is consistent with a recent study
showing a wide range of plasma OXT in pregnant subjects,16
though at odds with some studies where the plasma OXT did
not vary significantly among parturients during different
phases of labor.15,17,18 These contradictory observations
may partly be accounted for by differences in methodology
and sensitivity of reagents in detecting OXT. For example, the
choice of assay (radioimmunoassay vs. enzyme immunoas-
say) and the presence or absence of sample extraction to
minimize matrix interference could partly explain these
differences.19 Nevertheless, our data suggest that this sig-
nificant interindividual variability should be considered
when planning future studies. Another intriguing finding
was that plasma OXT decreased after OXT augmentation in
60% of parturients. These results defy principles of phar-
macotherapy where plasma levels are expected to rise after
IV administration. OXT, therefore, presumably behaves more
like a hormone in this setting and possibly exerts feedback
inhibition to suppress endogenous OXT release. However,
currently available ELISA kits are unable to differentiate
Fig. 3 Scatter plot of plasma oxytocinase level (ng/mL) in nonobese (in circles) and obese parturients (in squares) during labor induction and
augmentation at time T0 (open shapes) and T1 (closed shapes). Oxytocinase level was significantly lower at T0 (
p ¼ 0.03) but not at T1
(p ¼ 0.44). Data represented as median and interquartile range.
Table 3 Mixed-model repeated-measures ANOVA with and without group versus time interaction for oxytocin and oxytocinase








Oxytocin 0.88 0.49 0.51
Repeated measures Oxytocin 0.92 0.56 –
Repeated measures
with interaction term
Oxytocinase 0.55 0.11 0.09
Repeated measures Oxytocinase 0.76 0.22 –
Abbreviation: ANOVA, analysis of variance.
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between endogenous and exogenously administered OXT.
An important caveat in our study is the higher proportion of
cervical ripening in the obese group. This could have changed
OXT requirements during induction and augmentation. Con-
versely, cervical ripening could have affected our primary
outcome by elevating baseline OXT in obese subjects either
because of physicalmanipulation of the cervixor by inducing
mild uterine contractions. This, along with the small number
of paired samples, could possibly explain the significant
variability in plasma OXT in the obese group despite similar
duration of OXT administration. Our study, therefore,
encourages a nuanced understanding of the role of OXT in
labor management especially considering that it plays a vital
role in areas unrelated to labor such as sexual function,
learning, and memory.20,21
Despite the extensive and ubiquitous use of OXT for
management of labor and delivery, not much is known of
its metabolism. Numerous studies have attempted to answer
this question by measuring the “activity” of oxytocinase
(LNPEP), an enzyme secreted by the placenta that degrades
circulating OXT.22–26 Quantitation of oxytocinase “activity”
is done fluorometrically by measuring the amount of β-
naphthylamine released from an arylamide substrate after
incubation with plasma.27 Here, we quantified for the first
time, plasma oxytocinase level, rather than activity, and
report that it is lower in obese women at baseline compared
with nonobese women. As oxytocinase is secreted primarily
by syncytiotrophoblasts,24we speculate that this decrease is
likely related to placental dysfunction observed in obesity.28
Another interesting finding was that the cumulative OXT
dose significantly influenced the oxytocinase level at T1.
Though the biological significance of these findings is
unclear, wehope that our datawill encourage future research
in this field.
Our study is limited in some ways. First, the lack of serial
plasma OXT data to thoroughly characterize its pharmaco-
kinetics. This was ethically challenging given the need for
multiple blood draws during what was already a stressful
period for an expectant mother. Despite our decision to
collect samples at only two time points, T0 and T1, we
were still unable to collect the T1 sample in one-third
(36%) of the enrolled subjects (patient refusal in advanced
labor, after hours sample collection, etc.). Furthermore, given
the need for immediate sample processingon ice tominimize
OXT degradation, it would have been impossible to process
multiple samples sequentially on a busy labor and delivery
floor. These practical and logistic challenges will serve to
inform patient recruitment for future studies. Our study,
therefore, can be considered as a preliminary exploration of
Table 4 Mixed-model repeated-measures ANOVA with and without group versus time interaction for oxytocin and oxytocinase













62 Oxytocin 0.74 0.43 0.46 0.65
Repeated measures 62 Oxytocin 0.74 0.51 – 0.64
Repeated measures
with interaction term
56 Oxytocinase 0.47 0.27 0.22 <0.0001
Repeated measures 56 Oxytocinase 0.44 0.42 – <0.0001
Abbreviation: ANOVA, analysis of variance.
Table 5 Mixed-model repeated-measures ANOVA with and without group versus time interaction for oxytocin and oxytocinase











62 Oxytocin 0.76 0.43 0.45
Repeated measures 62 Oxytocin 0.77 0.51 –
Repeated measures
with interaction term
56 Oxytocinase 0.47 0.25 0.20
Repeated measures 56 Oxytocinase 0.44 0.42 –
Abbreviation: ANOVA, analysis of variance.
Table 6 ANCOVA to adjust for baseline differences in oxytocin
and oxytocinase





ANCOVA Oxytocin 0.45 0.34
ANCOVA Oxytocinase 0.23 0.72
Abbreviation: ANCOVA, analysis of covariance.
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OXT disposition in normal weight and obese parturients.
Second, the possibility that OXT is metabolized by pathways
other than LNPEP (“oxytocinase”). Nevertheless, we targeted
LNPEP as it appears to be the predominant mechanism for
OXT degradation in pregnant plasma.29,30 Third, because of
the limited number of paired samples, we were underpow-
ered to investigate the magnitude of change in plasma OXT
and oxytocinase both in nonobese and obese subjects.
Fourth, we chose prepregnancy BMI for patient recruitment
as this was more reliably documented than the BMI on
admission. It is reassuring though, that the average gesta-
tional weight gain was comparable between the two groups.
Finally, because of our interest in quantifying both OXT and
oxytocinase from the same sample, we did not use aprotinin,
an agent administered to inhibit oxytocinase and prevent
OXT degradation. Though this may have introduced some
variability, we expect this to be consistent across both
groups.
In conclusion, our preliminary study shows that plasma
OXT is no different in nonobese and obese parturients, and
that OXT augmentation is not accompanied by an increase in
plasma OXT in a majority of patients regardless of BMI.
Plasma oxytocinase was lower in obese parturients at induc-
tion, but it did not seem to influence plasma OXT during
augmentation of labor. Therefore, our results lend support to
the notion that differences in labor outcomes between non-
obese and obese women are probably driven bymechanisms
other than simple differences in OXT disposition. However,
given the potential clinical implications, we encourage a
sample-intensive study to thoroughly characterize OXT
pharmacokinetics in nonobese and obese women.
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